What is Leerink Partnrs' Estimate for GPCR Q4 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) - Equities researchers at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for shares of Structure Therapeutics in a research note issued on Monday, March 3rd. Leerink Partnrs analyst D. Risinger anticipates that the company will post earnings per share of $2.58 for the quarter. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics' FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at ($1.53) EPS.

A number of other brokerages have also issued reports on GPCR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus initiated coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 price objective for the company. William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Finally, JMP Securities restated a "market outperform" rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and an average target price of $81.29.

Remove Ads

Structure Therapeutics Price Performance

GPCR traded down $0.91 on Wednesday, reaching $22.62. The company's stock had a trading volume of 636,425 shares, compared to its average volume of 823,078. The business's 50 day moving average is $25.98 and its 200 day moving average is $33.05. Structure Therapeutics has a 1 year low of $19.61 and a 1 year high of $62.74. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -30.57 and a beta of -2.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after acquiring an additional 553 shares during the period. GAMMA Investing LLC boosted its position in Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics in the fourth quarter valued at approximately $34,000. FNY Investment Advisers LLC acquired a new stake in Structure Therapeutics in the fourth quarter valued at approximately $40,000. Finally, Assetmark Inc. raised its stake in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after acquiring an additional 719 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.